 Antineoplastic Agents, Alkylating
"Antineoplastic Agents, Alkylating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
| Descriptor ID |
D018906
|
| MeSH Number(s) |
D27.505.519.124.035 D27.505.954.248.150 D27.888.569.035.035
|
| Concept/Terms |
Antineoplastic Agents, Alkylating- Antineoplastic Agents, Alkylating
- Antineoplastic Alkylating Agents
- Alkylating Agents, Antineoplastic
- Antineoplastic Drugs, Alkylating
- Antineoplastics, Alkylating
- Alkylating Antineoplastic Drugs
- Alkylating Drugs, Antineoplastic
- Antineoplastic Alkylating Drugs
- Drugs, Antineoplastic Alkylating
- Alkylating Antineoplastic Agents
- Alkylating Antineoplastics
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Alkylating".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Alkylating".
This graph shows the total number of publications written about "Antineoplastic Agents, Alkylating" by people in this website by year, and whether "Antineoplastic Agents, Alkylating" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 2 | 0 | 2 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2006 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2010 | 1 | 1 | 2 | | 2011 | 1 | 2 | 3 | | 2012 | 2 | 1 | 3 | | 2014 | 1 | 2 | 3 | | 2015 | 2 | 1 | 3 | | 2016 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents, Alkylating" by people in Profiles.
-
Voorhees PM, Usmani SZ. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy. Clin Adv Hematol Oncol. 2016 Sep; 14(9):719-28.
-
D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015 Nov 10; 33(32):3741-9.
-
Kim J, Lee IH, Cho HJ, Park CK, Jung YS, Kim Y, Nam SH, Kim BS, Johnson MD, Kong DS, Seol HJ, Lee JI, Joo KM, Yoon Y, Park WY, Lee J, Park PJ, Nam DH. Spatiotemporal Evolution of the Primary Glioblastoma Genome. Cancer Cell. 2015 Sep 14; 28(3):318-28.
-
Arvold ND, Tanguturi SK, Aizer AA, Wen PY, Reardon DA, Lee EQ, Nayak L, Christianson LW, Horvath MC, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Alexander BM. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):384-9.
-
Ramirez YP, Mladek AC, Phillips RM, Gynther M, Rautio J, Ross AH, Wheelhouse RT, Sakaria JN. Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. Mol Cancer Ther. 2015 Jan; 14(1):111-9.
-
Wong JR, Morton LM, Tucker MA, Abramson DH, Seddon JM, Sampson JN, Kleinerman RA. Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol. 2014 Oct 10; 32(29):3284-90.
-
Bai Y, Lathia JD, Zhang P, Flavahan W, Rich JN, Mattson MP. Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells. Glia. 2014 Oct; 62(10):1687-98.
-
Cooke DL, Stout CE, Kim WT, Hetts SW, Higashida RT, Halbach VV, Dowd CF, Gould RG. Radiation dose reduction in intra-arterial chemotherapy infusion for intraocular retinoblastoma. J Neurointerv Surg. 2014 Dec; 6(10):785-9.
-
Sosna J, Voigt S, Mathieu S, Lange A, Thon L, Davarnia P, Herdegen T, Linkermann A, Rittger A, Chan FK, Kabelitz D, Schütze S, Adam D. TNF-induced necroptosis and PARP-1-mediated necrosis represent distinct routes to programmed necrotic cell death. Cell Mol Life Sci. 2014 Jan; 71(2):331-48.
-
Mahmoud BH, Eide MJ. Bendamustine-induced "flagellate dermatitis". Dermatol Online J. 2012 Nov; 18(11):12.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|